Hepatitis C Treatment Market to Reach US$ 245.2 Billion by 2034, Driven by Government Initiatives and Rising Global Awareness

Integration of Telemedicine and Digital Platforms Enhances Patient Monitoring and Adherence in Hepatitis C Care.

The global hepatitis C treatment market is expected to reach US$ 71,133.3 million by 2024 and is forecast to reach a value of US$ 2,45,215.5 million by 2034, with a projected CAGR of 13.2% from 2024 to 2034. Leading manufacturers are developing and promoting hepatitis C treatments despite the negative factors. Government campaigns to increase knowledge about hepatitis and its treatment accelerate the growth of the hepatitis C treatment market.

Emerging countries like Brazil, China, and India have a larger patient pool than developed countries. As a result, there is a higher demand for hepatitis C treatment. Few countries and their governments have implemented initiatives to stop the spread of hepatitis C, such as subsidizing specific treatments or allocating extra funds for programs that address the infection. Many for-profit organizations educate and increase public awareness of the hepatitis C virus. These can be considered market factors for hepatitis C treatments.

Regional Outlook

The lucrative revenue share from North America is anticipated from 2024 to 2034. The population's growing health consciousness propels the demand for improved hepatitis C virus (HCV) treatment alternatives. The market expansion of hepatitis C treatment is likely to be accelerated by rising healthcare costs and the availability of treatment options. These factors compel the growth of the hepatitis C treatment market in North America.

Asia Pacific's hepatitis C treatment market is expected to expand at a noteworthy 15.5% CAGR by 2033. The number of elderly people is rising significantly in nations like China and India. Growth in healthcare facilities and the existence of generic producers are the primary catalysts of revenue growth. These crucial elements are going to boost the rise of hepatitis C virus treatment market revenue between 2024 and 2034.

For More Insights into the Market, Request a Sample of this Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=9435

Key Takeaways

• The combination therapy segment in the drug class category is expected to grab a share of 74.6% by 2034.
• The combination therapy segment in the drug class category is anticipated to exhibit a CAGR of 13.9% from 2024 to 2034.
• By distribution channel category, the hospital pharmacies segment is projected to acquire a market share of 44.4% by 2034.
• The online pharmacies segment in the distribution channel category to develop a CAGR of 13.8% from 2024 to 2034.
• The North America hepatitis C treatment market is anticipated to surge at a CAGR of 12.8% by 2034.
• East Asia's hepatitis C treatment industry is likely to develop at a CAGR of 15.5% through 2034.
• The United States sales of hepatitis C treatment are anticipated to surge at a CAGR of 13.2% by 2034.
• Canada's hepatitis C treatment market to develop at a CAGR of 11.0% through 2034.
• Mexico's sales of hepatitis C treatment are anticipated to evolve at a CAGR of 9.6% by 2034.
• China hepatitis C treatment sales are expected to surge at a CAGR of 15.8% until 2034.
• Japan's hepatitis C virus treatment market to exhibit a CAGR of 15.2% by 2034.
• South Korea's hepatitis C treatment industry is anticipated to boost at a CAGR of 15.4% by 2034.

“Recent technological advancements, rising awareness, and changing treatment environments define the hepatitis C virus treatment market. Opportunities for hepatitis C treatment market expansion are highlighted by rising prevalence, diagnosis rates, and continuing research; moreover, impediments to access and cost still need to be addressed.” Says a Fact.MR Analyst

Competitive Landscape

Market competition for hepatitis C treatment is intense and is fueled by strategic alliances, continuous research, and regulatory advancements. Significant hepatitis C treatment vendors compete to be the market leader by focusing on cost, effectiveness of therapy, and accessibility globally. The hepatitis C treatment market landscape is dynamic, with established pharmaceutical players and emerging biotech companies focusing on unmet medical needs.

Get Customization on this Report for Specific Research Solutions-https://www.factmr.com/connectus/sample?flag=S&rep_id=9435

Noteworthy Developments

• Since February 2022, an observational study has been conducted to assess the impact of direct-acting antivirals on the mother-infant outcome following prenatal treatment for hepatitis C.
• In June 2021, a multicenter trial that treated acute hepatitis C over eight weeks with a fixed dosage combination of sofosbuvir and velpatasvir ended.

Key Companies Profiled-

Bristol-Myers Squibb Company; Gilead Sciences, Inc.; Abbvie; Kadmon Holdings Inc.; F. Hoffmon La Roche Ltd.; GlaxoSmithKline; Johnson & Johnson; Lupin Pharmaceuticals, Inc.; Merck & Co., Inc.; Teva Pharmaceuticals; Zydus Pharmaceuticals

Industry News-

An observational study evaluating the effects of direct-acting antivirals on the mother-infant outcome after antenatal treatment for hepatitis C has been ongoing since February 2022.

A multicenter trial using a fixed dosage combination of sofosbuvir andvelpatasvir for treating acute hepatitis C over eight weeks was concluded in June 2021.

In April 2019, the U.S. Food and Drug Administration (FDA) approved Mavyret (glecaprevir and pibrentasvir) tablets for the treatment of children 12 to 17 years old with all six genotypes of the hepatitis C virus (HCV). Mavyret was approved in 2017 to treat adult HCV.

Explore More Related Studies Published by Fact.MR Research:

Human Umbilical Vein Endothelial Cells (HUVEC) Market Analysis By Type (Single Donors, Pooled Donors), By Application (Wound Healing, Angiogenesis, Oncology, Tissue Engineering), By Region - Global Insights 2021 to 2031

Worldwide demand for novel drug delivery systems (NDDS) is predicted to surge at a CAGR of 6.6% from 2022 to 2027. At present, the global novel drug delivery systems market enjoys a valuation of US$ 62.5 billion and is anticipated to climb to a market size of US$ 86 billion by the end of 2027.

The global venous stents market size was valued at US$ 1.08 Billion in 2022, and is projected to reach US$ 2.44 Billion by 2032, growing at a CAGR (Compound Annual Growth Rate) of 8.5% during the forecast period from 2022 to 2032.

The global aesthetic medicine market size in 2021 was held at US$ 64.6 billion. With 10.3%, the projected market growth during 2022 to 2032 is expected to be significantly higher than the historical growth.

The global transcatheter valve replacement market is valued at US$ 3.6 billion. The market is projected to expand at an impressive CAGR of 13.4% and generate an absolute dollar opportunity worth US$ 9.2 billion over the assessment period (2022 to 2032).